NCT04832971

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 204 (actual)
• Sponsor: Arrowhead Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.

Conditions

• Mixed Dyslipidemia

Interventions

Type	Name	Description
DRUG	ARO-ANG3	ARO-ANG3 Injection
DRUG	Placebo	Sterile Normal Saline (0.9% NaCl)

Timeline

• Start date: 2021-06-28
• Primary completion: 2022-08-30
• Completion: 2024-09-25
• First posted: 2021-04-06
• Last updated: 2025-12-03
• Results posted: 2024-01-16

Locations

24 sites across 4 countries: United States, Australia, Canada, New Zealand

Regulatory

• FDA-regulated drug study